A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Abatacept (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ASSET
- 06 Mar 2018 Planned End Date changed from 1 Feb 2019 to 28 Sep 2018.
- 06 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 28 Sep 2018.
- 09 Mar 2017 Status changed from recruiting to active, no longer recruiting.